Literature DB >> 21762243

Therapeutic application of ultrasound-guided 8-gauge Mammotome system in presumed benign breast lesions.

Hao-jun Luo1, Xin Chen, Gang Tu, Jing Wang, Cheng-yi Wu, Guang-lun Yang.   

Abstract

The stereotactic or ultrasound-guided vacuum-assisted breast biopsy (Mammotome, MMT) system is a minimally invasive surgical technique. Increasingly, it is used to remove benign breast lesions as management. To evaluate the therapeutic value of 8-gauge ultrasound-guided MMT system (UMS) in presumed benign breast lesions, a retrospective analysis was performed on a series of 2,167 consecutive 8-gauge UMS procedures. The parameters used in this analysis included lesion size, location, breast imaging reporting and data system for ultrasound category, histopathologic diagnosis, and others. A total of 1,119 women whose mean ages were 36.6 years (range: 12-71, SD: 9.6) underwent 2,167 consecutive 8-gauge UMS procedures. Among the patients, 298 cases (26.63%) did not have palpable mass, 430 (38.43%) had multiple lesions, and 237 (21.18%) had bilateral ones. The average size of excised lesions was 15.8 mm (range: 5-55, SD: 6.7) in the largest dimension, including 294 lesions < 10 mm (13.57%); 1,359 lesions, 10-19 mm (62.71%); 420 lesions, 20-29 mm (19.38%), and 94 lesions ≥ 30 mm (4.34%). Predominant lesions (81.59%) were solid on ultrasound image and nearly half (48.59%) of them were localized in the upper outer quadrant. Histopathologic diagnosis revealed that the overwhelming majority of specimens (96.61%) were benign, most of which manifested as fibroadenoma and fibrocystic changes, while high-risk lesions were revealed in 31 (2.29%) cases and malignancies in 15 (1.11%). Average time for procedure was 8.6 minutes (range: 3.5-38, SD: 5.4) and mean number of cores removed in the procedure was 9.3 (range: 2-42, SD: 3.7). Complete excision was achieved predominantly (99.82%). Complications (59, 5.27%) in which hematoma (41, 3.66%) was the majority were acceptable. In conclusion, the 8-gauge UMS procedure is a safe and potent therapeutic management with satisfactory cosmetic outcome for benign and high-risk breast lesions, especially for bilateral, multiple, and nonpalpable ones. It is a reliable biopsy tool for suspected lesions as well. Eradication and maximal cosmesis can be achieved with few complications if the targeted lesion is limited to 30 mm.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21762243     DOI: 10.1111/j.1524-4741.2011.01125.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  13 in total

1.  Percutaneous ultrasound-guided vacuum-assisted excision of benign breast lesions: A learning curve to assess outcomes.

Authors:  Juan Pablo Salazar; Ignacio Miranda; Juan de Torres; María N Rus; Martin Espinosa-Bravo; Antonio Esgueva; Rafael Salvador; Isabel T Rubio
Journal:  Br J Radiol       Date:  2018-11-29       Impact factor: 3.039

2.  Feasibility and safety of image-guided vacuum-assisted breast biopsy: A PRISMA-compliant systematic review and meta-analysis of 20 000 population from 36 longitudinal studies.

Authors:  Ming Fang; Guilin Liu; Guoliang Luo; Tianyu Wu
Journal:  Int Wound J       Date:  2019-09-18       Impact factor: 3.315

3.  Minimally Invasive Breast Fibroadenoma Excision Using an Ultrasound-Guided Vacuum-Assisted Biopsy Device.

Authors:  Thomas Papathemelis; Stefanie Heim; Michael P Lux; Ines Erhardt; Anton Scharl; Sophia Scharl
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-02       Impact factor: 2.915

4.  Ultrasound-guided vacuum-assisted breast biopsy using Mammotome biopsy system for detection of breast cancer: results from two high volume hospitals.

Authors:  Shaobo Pan; Wenguang Liu; Ketao Jin; Yu Liu; Yunxiao Zhou
Journal:  Int J Clin Exp Med       Date:  2014-01-15

5.  Prediction of postoperative hematoma occurrence after ultrasound-guided vacuum-assisted breast biopsy in minimally invasive surgery for percutaneous removal of benign breast lesions.

Authors:  Jianwei Zheng; Shuyan Cai; Huimin Song; Yunlei Wang; Xiaofeng Han; Gang Han; Haoliang Wu; Zhigang Gao
Journal:  Gland Surg       Date:  2020-10

Review 6.  Status quo and development trend of breast biopsy technology.

Authors:  Yan-Jun Zhang; Lichun Wei; Jie Li; Yi-Qiong Zheng; Xi-Ru Li
Journal:  Gland Surg       Date:  2013-02

Review 7.  Minimally invasive surgical management of benign breast lesions.

Authors:  Anna Lakoma; Eugene S Kim
Journal:  Gland Surg       Date:  2014-05

8.  Nonsurgical management of fibroadenoma and virginal breast hypertrophy.

Authors:  Sandhya Pruthi; Katie N Jones
Journal:  Semin Plast Surg       Date:  2013-02       Impact factor: 2.314

9.  Patient reported cosmetic outcome after vacuum assisted excision of benign breast lesions: a cross-sectional study.

Authors:  Elles M F van de Voort; Taco M A L Klem; Gerson M Struik; Erwin Birnie; Renata H J A Sinke; Ali Ghandi
Journal:  Br J Radiol       Date:  2020-07-20       Impact factor: 3.039

10.  Mammotome® biopsy system for the resection of breast lesions: Clinical experience in two high-volume teaching hospitals.

Authors:  Yangping Jiang; Huanrong Lan; Qian Ye; Ketao Jin; Min Zhu; Xiaoyan Hu; Lisong Teng; Feilin Cao; Xianfang Lin
Journal:  Exp Ther Med       Date:  2013-07-01       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.